These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 9803483)

  • 1. Oxidation resistance of LDL in hypertriglyceridaemic patients treated with ciprofibrate.
    Nagyová A; Raslová K; Ginter E
    Physiol Res; 1998; 47(3):185-90. PubMed ID: 9803483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ciprofibrate treatment in patients with atherogenic lipoprotein phenotype: effects on HDL quality, LDL susceptibility to oxidation and DNA damage.
    Raslová K; Dobiásová M; Nagyová A; Fábry R; Rauchová H; Dusinská M
    Eur J Clin Pharmacol; 1998; 54(9-10):697-9. PubMed ID: 9923570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease.
    Kontopoulos AG; Athyros VG; Papageorgiou AA; Hatzikonstandinou HA; Mayroudi MC; Boudoulas H
    Coron Artery Dis; 1996 Nov; 7(11):843-50. PubMed ID: 8993943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of ciprofibrate on lipoprotien metabolism and oxidative stress parameters in patients with type 2 diabetes mellitus and atherogenic lipoprotein phenotype.
    Raslová K; Nagyová A; Dobiásová M; Ptácková K; Dusinská M
    Acta Diabetol; 2000; 37(3):131-4. PubMed ID: 11277313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia.
    Stalenhoef AF; de Graaf J; Wittekoek ME; Bredie SJ; Demacker PN; Kastelein JJ
    Atherosclerosis; 2000 Nov; 153(1):129-38. PubMed ID: 11058707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemfibrozil treatment potentiates oxidative resistance of high-density lipoprotein in hypertriglyceridemic patients.
    Chen MF; Wang TD; Yeh HT; Hsu HC; Lee YT
    Eur J Clin Invest; 2001 Aug; 31(8):707-13. PubMed ID: 11473572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia.
    Bruckert E; Dejager S; Chapman MJ
    Atherosclerosis; 1993 Apr; 100(1):91-102. PubMed ID: 8318067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.
    Olsson AG; Orö L
    Atherosclerosis; 1982 Apr; 42(2-3):229-43. PubMed ID: 6951582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux.
    Guerin M; Le Goff W; Frisdal E; Schneider S; Milosavljevic D; Bruckert E; Chapman MJ
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3738-46. PubMed ID: 12915663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes.
    Rizos E; Bairaktari E; Ganotakis E; Tsimihodimos V; Mikhailidis DP; Elisaf M
    J Cardiovasc Pharmacol Ther; 2002 Oct; 7(4):219-26. PubMed ID: 12490967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ciprofibrate increases paraoxonase activity in patients with metabolic syndrome.
    Paragh G; Seres I; Harangi M; Erdei A; Audikovszky M; Debreczeni L; Kovácsay A; Illyés L; Pados G
    Br J Clin Pharmacol; 2006 Jun; 61(6):694-701. PubMed ID: 16722831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of ciprofibrate in hyperlipoproteinaemias.
    Turpin G; Bruckert E
    Atherosclerosis; 1996 Jul; 124 Suppl():S83-7. PubMed ID: 8831920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The atherogenic role of triglycerides and small, dense low density lipoproteins: impact of ciprofibrate therapy.
    Chapman MJ; Bruckert E
    Atherosclerosis; 1996 Jul; 124 Suppl():S21-8. PubMed ID: 8831912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sialic acid-containing components of lipoproteins influence lipoprotein-proteoglycan interactions.
    Millar JS; Anber V; Shepherd J; Packard CJ
    Atherosclerosis; 1999 Aug; 145(2):253-60. PubMed ID: 10488950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LDL oxidizability and antioxidative status of plasma in vegetarians.
    Nagyová A; Kudlácková M; Grancicová E; Magálová T
    Ann Nutr Metab; 1998; 42(6):328-32. PubMed ID: 9895420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paradoxical high-density lipoprotein reduction induced by fenofibrate and ciprofibrate.
    Collinson PO; Hjelm CJ; Canepo-Anson R
    Ann Clin Biochem; 1996 Mar; 33 ( Pt 2)():159-61. PubMed ID: 8729728
    [No Abstract]   [Full Text] [Related]  

  • 17. [The effect of monotherapy with ciprofibrate and in combination with acetylsalicylic acid on the spectrum of lipids, thromboxane and fibrinogen in patients with atherosclerosis and hyperlipoproteinemia].
    Gajdos M; Fedelesova V; Mongiellova V; Cibulova L; Huttova D; Polak F; Krivosikova Z
    Bratisl Lek Listy; 1999 Aug; 100(8):449-53. PubMed ID: 10645034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HDL oxidability and its protective effect against LDL oxidation in Type 2 diabetic patients.
    Sanguinetti SM; Brites FD; Fasulo V; Verona J; Elbert A; Wikinski RL; Schreier LE
    Diabetes Nutr Metab; 2001 Feb; 14(1):27-36. PubMed ID: 11345163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ciprofibrate effects on carbohydrate and lipid metabolism in type 2 diabetes mellitus subjects.
    Hernández-Mijares A; Lluch I; Vizcarra E; Martínez-Triguero ML; Ascaso JF; Carmena R
    Nutr Metab Cardiovasc Dis; 2000 Feb; 10(1):1-6. PubMed ID: 10812581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of high-density lipoprotein subfractions inhibiting copper-catalyzed oxidation of low-density lipoprotein.
    Huang JM; Huang ZX; Zhu W
    Clin Biochem; 1998 Oct; 31(7):537-43. PubMed ID: 9812173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.